Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Minerva Neurosciences Inc
NERV | US
5.51
USD-0.51
-8.47%
NERV | US
About Minerva Neurosciences Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
10/04/2026
Close
5.51
Open
6.03
High
6.08
Low
5.48
Minerva Neurosciences Inc. a clinical-stage biopharmaceutical company focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia currently submitted an New Drug Application (NDA); and MIN-301 a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop sell and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals Inc. and changed its name to Minerva Neurosciences Inc. in 2013. Minerva Neurosciences Inc. was incorporated in 2007 and is headquartered in Waltham Massachusetts.
View LessNERV | US
Risk
88.5
Sharpe
1.72
Luna's Score
55/100
Recommendation
Hold
Luna says (NERV | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
What's not Working
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
92.3%1 month
88.5%3 months
114.9%6 months
225.0%Returns
Fundamental Ratios
PE
-
Fwd. PE
11.21
Price to book
2.68
Debt to equity
-1.95
Debt to assets
1.87
Ent. to EBITDA
2.60
Ent. to rev.
0.03
PEG
-
Other Fundamentals
EBITDA
-26.21M
MarketCap
38.53M
MarketCap(USD)
38.53M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-675.09
Short ratio
0.93
Short perc.
0.24
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
1.48
Range1M
3.78
Range3M
5.05
Volumes: Market Activity
Rel. volume
0.84
Price X volume
1.71M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 2.60 | - | Expensive |
| Ent. to Revenue | 0.03 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.68 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 114.87 | - | Riskier |
| Debt to Equity | -1.95 | -1.23 | Cheaper |
| Debt to Assets | 1.87 | 0.25 | Expensive |
| Market Cap | 38.53M | - | Emerging |
